Drug Landscape ›
Ferrous sulfate 325mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 54
Most-reported reactions
Death — 12 reports (22.22%) Gastrointestinal Haemorrhage — 9 reports (16.67%) Dyspnoea — 6 reports (11.11%) Anaemia — 5 reports (9.26%) Disease Progression — 4 reports (7.41%) Haemoglobin Decreased — 4 reports (7.41%) Mental Status Changes — 4 reports (7.41%) Vomiting — 4 reports (7.41%) Chest Pain — 3 reports (5.56%) Cough — 3 reports (5.56%)
Source database →
Ferrous sulfate 325mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ferrous sulfate 325mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Ferrous sulfate 325mg in United States?
University of Colorado, Denver is the originator. The local marketing authorisation holder may differ — check the official source linked above.